Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

Regardless of decisions made during the ACIP meeting, health insurance plans will continue to cover shots recommended by ACIP as of Sept 1.

Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.

This week’s podcast episode covers cervical cancer disparities, HPV awareness, depression risk, pharmacy CRC screening, and semaglutide approval for MASH.

EADV 2025: Data will highlight the PDE4 inhibitor's efficacy across diverse populations and 3 common skin conditions: seborrheic dermatitis, atopic dermatitis, and psoriasis.

EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.

EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.

The investigational ShiraTronics Migraine Therapy System delivered an average of 9.6 migraine-free days per month, reduced rescue medication use, and improved QOL.

In honor of Gynecologic Cancer Awareness Month, Ada Stewart, MD, emphasizes the vital role of primary care in ensuring every eligible woman receives cervical cancer screening and follow-up care.

EASD 2025: Findings from a subanalysis of the REDEFINE 1 phase 3 trial support Novo Nordisk's plan to advance cagrilintide into a dedicated clinical program this year.

Real-time continuous glucose monitoring significantly enhances glycemic control in gestational diabetes, reducing risks for large newborns compared to traditional methods.